Table 1 Clinicopathologic characteristics of 1674 patients with PCa treated with RARP according to nerve approach and clinical outcomes.

Age, years, median, (IQR)

67 (63,71)

Age, number

  < 65 years

557 (33.3)

  >  = 65 years

1115 (66.6)

 Unknown

2 (0.1)

PSA (ng/mL), median, (IQR)

7.5 (5.5,10.7)

PSA (ng/mL)

  < 10

1176 (70.3)

 10–19.99

385 (23.0)

  >  = 20

110 (6.4)

 Unknown

3 (0.3)

Clinical T stage

 1-2b

706 (42.1)

 2c

584 (34.9)

 3–4

380 (22.7)

 Unknown

4 (0.3)

Gleason score

 6

388 (23.2)

 7

853 (49.9)

 8–10

429 (25.6)

 Unknown

4 (0.3)

D’Amico risk classification

 High

688 (41.1)

 Intermediate

756 (45.2)

 Low

226 (13.4)

 Unknown

4 (0.3)

BMI (kg/m²), median, (IQR)

23.5 (21.8,25.5)

BMI group (kg/m²)

  < 18.5

38 (2.3)

 18.5–22.9

637 (38.1)

 23–24.9

472 (28.2)

 25–29.9

484 (28.9)

  >  = 30

33 (2)

 Unknown

10 (0.6)

Prostate volume preoperative group (cm³)

  < 35

864 (51.6)

  >  = 35

710 (42.4)

 Unknown

100 (6.0)

Neoadjuvant treatment

 None

1067 (63.7)

 ADT

166 (9.9)

 Anti-A

177 (10.6)

 NACHT

244 (14.6)

 Unknown

20 (1.2)

Preoperative potency

 No erection

669 (40)

 Erection

528 (31.5)

 Penetration

447 (26.7)

 Unknown

30 (1.8)

Operative time, min, (IQR)

171 (145,204)

Console time, min, (IQR)

119 (99,147)

Blood loss, mil, (IQR)

205.5 (125,350)

Nerve-sparing

  Yes

1188 (71)

 No

484 (29)

Pathologic T stage

  1-2b

388 (23.2)

 2c

1010 (60.3)

 3–4

276 (16.5)

Surgical margin

 Negative

1333 (79.6)

 Positive

341 (20.4)

Biochemical recurrence

 Absent

1500 (89.6)

 Present

161 (9.6)

 Unknown

13 (0.8)

Postoperative potency

 No erection

1140 (68.1)

 Erection

354 (21.2)

  Penetrate

111 (6.6)

  Unknown

69 (4.1)

90 days complications according to the Clavien–Dindo classifcation

  <  = 3a

1610 (96.2)

  >  = 3b

57 (3.4)

  Unknown

7 (0.4)

Pentafecta achievement

 Yes

249 (14.9)

 No

1353 (80.8)

 Unknown

72 (4.3)